Clinical trials: Dengue
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60…
- Trial name
- NCT03342898
- Testing
- YF-17D, TDV
- Where
- 11 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
The purpose of this study is to determine the incidence of dengue fever and to build capacity for dengue vaccine trials in dengue-endemic regions of South Asia.
- Trial name
- NCT02570152
- Testing
- Blood sample collection
- Where
- Sri Lanka
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
- Trial name
- NCT02193087
- Testing
- TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized
- Where
- 7 sites in United States
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
- Trial name
- NCT03746015
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Disease, Dengue Virus
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants…
- Trial name
- NCT05507450
- Testing
- V181 High-Potency Level, V181 Mid-Potency Level, V181 Low-Potency Level
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 1,271 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dengue, Dengue Vaccines
This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
The purpose of this study is to describe the burden of DENV illness among household members aged 6 months to 50 years of selected communities in Latin America and Southeast Asia.
- Trial name
- NCT02766088
- Testing
- Blood sample collection
- Where
- 2 sites in Mexico, Philippines
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
The aim of the study was to assess the immune response and the safety of different vaccination schedules of CYD dengue vaccine. The primary objectives of the study were: To demonstrate the non-inferiority of the immune response…
- Trial name
- NCT02628444
- Testing
- CYD Dengue Vaccine
- Where
- 6 sites in Colombia, Philippines
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Study of AT-752 in Patients With Dengue Infection
The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population.
- Trial name
- NCT05466240
- Testing
- AT-752
- Where
- 32 sites in Brazil, Colombia and 8 more
- Volunteers
- 21 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Healthy
GLS-5700 in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02809443
- Testing
- GLS-5700
- Where
- 3 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.
- Trial name
- NCT01134263
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- Where
- 8 sites in Australia
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a tetravalent CYD dengue vaccine dose administered about 5 years or more after the completion of a 3-dose vaccination schedule in Singapore.
- Trial name
- NCT02824198
- Testing
- CYD Dengue Vaccine (5 dose formulation)
- Where
- 3 sites in Singapore
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact.
- Trial name
- NCT04273217
- Testing
- AV-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02979535
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
- Where
- Mexico
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Dengue Fever
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01488890
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
- Where
- 7 sites in United States
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.
- Trial name
- NCT02948829
- Testing
- TDV
- Where
- 2 sites in Panama, Philippines
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
A Study of JNJ-64281802 for the Prevention of Dengue Infection
The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no…
- Trial name
- NCT05201794
- Testing
- JNJ-64281802
- Where
- 38 sites in Brazil, Colombia and 7 more
- Volunteers
- 1,595 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.
- Trial name
- NCT02623725
- Testing
- CYD Dengue Vaccine (5-dose formulation)
- Where
- 5 sites in Brazil, Colombia and 3 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
- Trial name
- NCT03341637
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Mexico
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
The purpose of this study is to investigate the antiviral activity of JNJ-64281802 versus placebo in terms of reduction of dengue virus (DENV) ribonucleic acid (RNA) in primary DENV infection.
- Trial name
- NCT04906980
- Testing
- JNJ-64281802
- Where
- Singapore
- Volunteers
- 5 people
- Sponsor
- Janssen Research & Development, LLC
Dengue Fever, Dengue Hemorrhagic Fever
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
The aim of the study was to evaluate the safety and immunogenicity of the Dengue vaccine in a population of special interest, such as HIV-positive adults previously exposed to dengue.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Immunodeficiency Virus
- Trial name
- NCT02741128
- Testing
- CYD Dengue Vaccine
- Where
- 4 sites in Brazil
- Volunteers
- 133 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company